Results 111 to 120 of about 45,806 (246)

Involvement of the ADAMTS13–von Willebrand factor axis in acute kidney injury in mice with liver cirrhosis

Hepatology Research, Volume 55, Issue 6, Page 844-858, June 2025.
Abstract Aim Hepatorenal syndrome‐induced acute kidney injury (AKI) comprises AKI and liver cirrhosis (LC) and is a risk factor for poor prognoses of patients with LC. Decreased a disintegrin‐like metalloproteinase with thrombospondin type 1 motif 13 (ADAMTS13) activity and increased von Willebrand factor (vWF) antigen levels are associated with LC ...
Masayoshi Takami, Norihisa Nishimura, Kosuke Kaji, Nobuyuki Yorioka, Hiroyuki Masuda, Hiroaki Takaya, Koh Kitagawa, Shinya Sato, Tadashi Namisaki, Hitoshi Yoshiji   +9 more
wiley   +1 more source

Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19

Annals of Hematology, 2020
Dear Editor: A 57-year-old woman with a history of hypertension and breast cancer in complete remission was seen in lateMarch 2020 at the emergency ward in a private clinic with dry cough, anosmia, and dysgeusia.
N. Albiol, R. Awol, R. Martino
semanticscholar   +1 more source

BMQ [PDF]

, 1963
BMQ: Boston Medical Quarterly was published from 1950-1966 by the Boston University School of Medicine and the Massachusetts Memorial ...
Antuna, Juan, Bagnoli, Thomas, Barber, Doris E., Cocchiarella, John P., Duke, Martin, Estes, J. Worth, Friedlander, Walter J., Goldsmith, Harry S., Gooding, Gretchen W., Goofman, Max L., Haseotes, Hytho V., Hass, Gerald, Hastings, A. Baird, Jackson, David R., Johnson, David S., Kechejian, Sarkis J., Kramer, Philip, Litman, George I., Madoff, Irving M., McLellan, Patricia A., O'Hara, Vincent S., Peabody, C. Newton, Pryles, Charles V., Small, Donald M., Tedeschi, Luke G., Walker, Sydney, III   +25 more
core  

The clinical use of platelet transfusions: A systematic literature review and meta‐analysis on behalf of the International Collaboration for Transfusion Medicine Guidelines

Transfusion, Volume 65, Issue 6, Page 1155-1169, June 2025.
Abstract Background Platelets are frequently transfused, but supply and potential harms highlight the importance of appropriate use. Study Design and Methods Our systematic review (SR) followed a predefined protocol. Eligible studies included SRs, randomized controlled trials (RCTs), and matched cohort observational studies between 1946 and March 2025.
Rachel Jug, Ursula La Rocca, Arwa Z. Al‐Riyami, Aarti Bathla, Ryan A. Metcalf, Sandra K. White, Simon J. Stanworth, Susan Nahirniak   +7 more
wiley   +1 more source

Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura.

New England Journal of Medicine, 2019
Managing Acquired TTP without Plasma Exchange A case of acquired thrombotic thrombocytopenic purpura is reported in a Jehovah’s Witness who had neurologic manifestations but would not accept plasma...
Deepak P. Chander, M. Loch, S. Cataland, J. George   +3 more
semanticscholar   +1 more source

A case of congenital TTP presenting with microganiopathy in adulthood [PDF]

, 2014
BACKGROUND: Congenital thrombotic thrombocytopenic purpura (TTP), also known as Upshaw-Schulman Syndrome is a rare inherited deficiency of ADAMTS13. Unlike the more common acquired TTP which is characterized by an acquired inhibitor of ADAMTS13, patients
Andrea K Kew, Chris D Gallivan, David M Conrad   +2 more
core   +1 more source

Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine

Research and Practice in Thrombosis and Haemostasis, 2018
Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy characterized by severe congenital or immune‐mediated deficiency in ADAMTS13, the enzyme that cleaves von Willebrand factor multimers.
P. Coppo, A. Cuker, J. George
semanticscholar   +1 more source

Idiopathic combined, autoantibody-mediated ADAMTS-13/factor H deficiency in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in a 17-year-old woman: a case report

Journal of Medical Case Reports, 2011
Introduction Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome is a life-threatening condition with various etiopathogeneses. Without therapy approximately 90% of all patients die from the disease. Case presentation We report the case of a 17-
Patschan Daniel, Korsten Peter, Behlau Arne, Vasko Radovan, Heeg Malte, Sweiss Nadera, Müller Gerhard A, Koziolek Michael   +7 more
doaj   +1 more source

Conformational activation of ADAMTS13 [PDF]

, 2014
A disintegrin and metalloprotease with thrombospondin motifs 13 (ADAMTS13) is a metalloprotease that regulates von Willebrand factor (VWF) function. ADAMTS13-mediated proteolysis is determined by conformational changes in VWF, but also may depend on its ...
Collins, RF, Crawley, JTB, Deforche, L, Lane, DA, Luken, BM, Phillips, R, South, K, Thomas, M, Vanhoorelbeke, K   +8 more
core   +1 more source

Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura

Expert Review of Clinical Pharmacology, 2019
Introduction: Caplacizumab is a humanized anti-von Willebrand Factor (vWF) Nanobody® for the treatment of acquired Thrombotic Thrombocytopenic Purpura (aTTP). Caplacizumab targets the A1-domain of vWF, inhibiting the interaction between vWF and platelets.
M. Sargentini‐Maier, Philip De Decker, C. Tersteeg, J. Canvin, F. Callewaert, H. de Winter   +5 more
semanticscholar   +1 more source